KALA logoKALA
Kala Pharmaceuticals Inc

8,886
Loading...
Loading...
News
all
press releases
Wall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to Trade
The mean of analysts' price targets for KALA BIO (KALA) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·28d ago
News Placeholder
More News
News Placeholder
Zacks.com featured highlights include KALA, Graham, Arq and Hawkins
KALA, GHM, ARQ, and HWKN are drawing investor attention after fresh analyst coverage highlights improving outlooks.
Zacks·1mo ago
News Placeholder
Analyst Coverage Sparks Interest in These 4 Stocks Amid Volatility
New analyst coverage lifts investor interest in KALA, GHM, ARQ, and HWKN as markets grapple with rising volatility.
Zacks·2mo ago
News Placeholder
Kala Bio Stock Sinks On CEO Exit, But Retail Feels It’s An Overreaction
Kala is set to report mid-stage trial data in the second quarter for KPI-012, its experimental treatment for persistent corneal epithelial defects.
Stocktwits·7mo ago
News Placeholder
KALA Stock Earnings: Kala Pharmaceuticals Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips KALA stock results show that Kala Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023. The post...
InvestorPlace·1y ago
News Placeholder
Kala Pharmaceuticals GAAP EPS of -$3.18 beats by $0.44
Kala Pharmaceuticals GAAP EPS of -$3.18 beats by $0.44...
SeekingAlpha.com: All News·1y ago
News Placeholder
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 ---- Exploring opportunities to expand KPI-012 into additional corneal indications ---- Cash...
Globe Newswire·1y ago
News Placeholder
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
Globe Newswire·2y ago
News Placeholder
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
ARLINGTON, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
Globe Newswire·2y ago
News Placeholder
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ARLINGTON, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award...
Globe Newswire·2y ago

Latest KALA News

View

Advertisement. Remove ads.

Advertisement. Remove ads.